Ibritumomab tiuxetan

From WikiMD.org
Jump to navigation Jump to search

Ibritumomab Tiuxetan (pronounced as eye bri too moe' mab tye ux' e tan) is a monoclonal antibody that is used in the treatment of certain types of non-Hodgkin lymphoma. It is marketed under the trade name Zevalin.

Etymology

The name "Ibritumomab Tiuxetan" is derived from the components of the drug. "Ibri" is an abbreviation for the company that developed the drug, IDEC Pharmaceuticals. "Tumomab" indicates that it is a tumor-targeting monoclonal antibody. "Tiuxetan" refers to the chelator that is used to attach the radioactive isotope to the antibody.

Usage

Ibritumomab Tiuxetan is used to treat patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin lymphoma, including patients with rituximab-refractory follicular non-Hodgkin lymphoma.

Mechanism of Action

Ibritumomab Tiuxetan is a radioimmunotherapy agent. It consists of a monoclonal antibody that targets the CD20 antigen on the surface of B-cells, and a radioactive isotope (Yttrium-90 or Indium-111), which delivers a dose of radiation to the targeted cells.

Side Effects

Common side effects of Ibritumomab Tiuxetan include anemia, neutropenia, thrombocytopenia, fever, and infection. Severe side effects may include myelodysplastic syndrome and leukemia.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski